Samrat Pharmachem Ltd
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]
- Market Cap ₹ 105 Cr.
- Current Price ₹ 339
- High / Low ₹ 534 / 320
- Stock P/E 48.5
- Book Value ₹ 210
- Dividend Yield 0.29 %
- ROCE 4.14 %
- ROE 3.37 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Tax rate seems low
- Earnings include an other income of Rs.1.38 Cr.
- Debtor days have increased from 73.9 to 89.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
72 | 65 | 47 | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 311 | 282 | |
71 | 64 | 46 | 62 | 69 | 87 | 108 | 131 | 170 | 197 | 287 | 279 | |
Operating Profit | 1 | 1 | 1 | 1 | 4 | 6 | 3 | 7 | 9 | 24 | 24 | 2 |
OPM % | 2% | 1% | 2% | 2% | 5% | 6% | 3% | 5% | 5% | 11% | 8% | 1% |
1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Profit before tax | 1 | 0 | 0 | 0 | 3 | 5 | 2 | 6 | 7 | 24 | 23 | 3 |
Tax % | 31% | 41% | 35% | 33% | 37% | 35% | 29% | 27% | 27% | 27% | 26% | 14% |
0 | 0 | 0 | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 2 | |
EPS in Rs | 1.29 | 0.78 | 1.04 | 0.97 | 5.66 | 10.42 | 4.98 | 13.72 | 17.25 | 55.60 | 53.82 | 6.99 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% | 2% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 20% |
3 Years: | 16% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 7% |
3 Years: | -26% |
TTM: | -87% |
Stock Price CAGR | |
---|---|
10 Years: | 31% |
5 Years: | 37% |
3 Years: | 14% |
1 Year: | -30% |
Return on Equity | |
---|---|
10 Years: | 19% |
5 Years: | 22% |
3 Years: | 23% |
Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 10 | 10 | 10 | 11 | 12 | 15 | 17 | 21 | 27 | 44 | 60 | 62 |
4 | 3 | 3 | 6 | 7 | 9 | 7 | 9 | 9 | 8 | 19 | 8 | |
17 | 15 | 10 | 17 | 14 | 13 | 14 | 25 | 19 | 30 | 34 | 48 | |
Total Liabilities | 34 | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 | 122 |
4 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 9 | 10 | 11 | 11 | |
CWIP | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
27 | 24 | 19 | 27 | 29 | 34 | 33 | 50 | 48 | 75 | 104 | 108 | |
Total Assets | 34 | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 | 122 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-2 | 4 | -1 | -0 | -3 | 0 | 2 | -1 | 5 | 17 | -9 | 9 | |
-1 | -0 | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | -3 | -0 | |
1 | -1 | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | 10 | -11 | |
Net Cash Flow | -2 | 2 | -0 | -0 | -1 | -1 | 1 | -1 | -0 | 14 | -3 | -2 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60 | 63 | 74 | 93 | 59 | 86 | 69 | 74 | 67 | 72 | 60 | 90 |
Inventory Days | 54 | 45 | 38 | 37 | 41 | 31 | 28 | 55 | 25 | 24 | 43 | 28 |
Days Payable | 89 | 87 | 76 | 104 | 43 | 46 | 45 | 67 | 39 | 45 | 42 | 64 |
Cash Conversion Cycle | 25 | 21 | 36 | 26 | 58 | 70 | 52 | 61 | 53 | 51 | 61 | 53 |
Working Capital Days | 37 | 25 | 39 | 35 | 61 | 65 | 56 | 63 | 54 | 44 | 62 | 58 |
ROCE % | 9% | 7% | 7% | 5% | 16% | 23% | 12% | 22% | 24% | 52% | 35% |
Documents
Announcements
- Closure of Trading Window 29 Jun
- Board Meeting Intimation for Un-Audited Financial Results For The Quarter Ended June 30, 2024 29 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Jun - Newspaper Publication - Extract of Audited Financial Results for the year ended March 31, 2024
- Audited Financial Results For The Year Ended March 31, 2024 30 May
- Board Meeting Outcome for Outcome Of The Board Meeting Held Today 30 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
SPL manufactures pharmaceutical ingredient products. It is a major supplier of Iodine Derivatives to the Indian and Foreign Market
and is also present in Salt, Animal Feed, Textile & Tyre Cord manufacturing segment. Company's facilities approved by leading regulatory agencies such as USFDA, GMP, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA